Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.37)
# 390
Out of 4,711 analysts
75
Total ratings
50.94%
Success rate
20.52%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EWTX Edgewise Therapeutics | Maintains: Outperform | $45 → $50 | $30.78 | +62.44% | 2 | Dec 17, 2024 | |
| SWTX SpringWorks Therapeutics | Initiates: Outperform | $60 | $35.59 | +68.59% | 1 | Nov 20, 2024 | |
| BNTX BioNTech SE | Upgrades: Outperform | $110 → $125 | $113.08 | +10.54% | 4 | Nov 19, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | $115 → $105 | $65.66 | +59.91% | 12 | Oct 30, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,250 → $1,175 | $701.85 | +67.41% | 5 | Oct 24, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $50 → $45 | $26.49 | +69.88% | 2 | Aug 7, 2024 | |
| MRNA Moderna | Maintains: In-Line | $120 | $39.39 | +204.65% | 4 | Jun 27, 2024 | |
| ACLX Arcellx | Initiates: Outperform | $85 | $75.54 | +12.52% | 1 | May 14, 2024 | |
| NBIX Neurocrine Biosciences | Initiates: Outperform | $175 | $135.42 | +29.23% | 1 | May 14, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $84 → $88 | $44.22 | +99.00% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $146.47 | +88.43% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $1.65 | +2,021.21% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,520 → $780 | $8.50 | +9,076.47% | 5 | Feb 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $263.38 | -11.91% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $68.84 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $92.57 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $29.71 | -29.32% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $2.75 | +736.36% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $0.71 | +1,299.19% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $310 → $250 | $12.72 | +1,865.41% | 1 | Feb 14, 2018 |
Edgewise Therapeutics
Dec 17, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $30.78
Upside: +62.44%
SpringWorks Therapeutics
Nov 20, 2024
Initiates: Outperform
Price Target: $60
Current: $35.59
Upside: +68.59%
BioNTech SE
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $113.08
Upside: +10.54%
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $65.66
Upside: +59.91%
Regeneron Pharmaceuticals
Oct 24, 2024
Maintains: Outperform
Price Target: $1,250 → $1,175
Current: $701.85
Upside: +67.41%
BridgeBio Pharma
Aug 7, 2024
Maintains: Outperform
Price Target: $50 → $45
Current: $26.49
Upside: +69.88%
Moderna
Jun 27, 2024
Maintains: In-Line
Price Target: $120
Current: $39.39
Upside: +204.65%
Arcellx
May 14, 2024
Initiates: Outperform
Price Target: $85
Current: $75.54
Upside: +12.52%
Neurocrine Biosciences
May 14, 2024
Initiates: Outperform
Price Target: $175
Current: $135.42
Upside: +29.23%
Ultragenyx Pharmaceutical
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $44.22
Upside: +99.00%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $146.47
Upside: +88.43%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $1.65
Upside: +2,021.21%
Feb 17, 2021
Downgrades: Neutral
Price Target: $1,520 → $780
Current: $8.50
Upside: +9,076.47%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $263.38
Upside: -11.91%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $68.84
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $92.57
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $29.71
Upside: -29.32%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $2.75
Upside: +736.36%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $0.71
Upside: +1,299.19%
Feb 14, 2018
Maintains: Neutral
Price Target: $310 → $250
Current: $12.72
Upside: +1,865.41%